Non-alcoholic Fatty Liver Disease and Mortality Among US Adults: Prospective Cohort Study

Overview

Journal BMJ

Specialty General Medicine

Date 2011 Nov 22

PMID 22102439

Citations 167

Authors

Mariana Lazo

Ruben Hernaez

Susanne Bonekamp

Ihab R Kamel

Frederick L Brancati

Eliseo Guallar

Jeanne M Clark

Affiliations

Soon will be listed here.

Abstract

Objective: To evaluate the association between non-alcoholic fatty liver disease and all cause and cause specific mortality in a representative sample of the US general population.

Design: Prospective cohort study.

Setting: US Third National Health and Nutrition Examination Survey (NHANES III: 1988-94) with follow-up of mortality to 2006.

Participants: 11,371 adults aged 20-74 participating in the Third National Health and Nutrition Examination Survey, with assessment of hepatic steatosis.

Main Outcome Measure: Mortality from all causes, cardiovascular disease, cancer, and liver disease (up to 18 years of follow-up).

Results: The prevalence of non-alcoholic fatty liver disease with and without increased levels of liver enzymes in the population was 3.1% and 16.4%, respectively. Compared with participants without steatosis, those with non-alcoholic fatty liver disease but normal liver enzyme levels had multivariate adjusted hazard ratios for deaths from all causes of 0.92 (95% confidence interval 0.78 to 1.09), from cardiovascular disease of 0.86 (0.67 to 1.12), from cancer of 0.92 (0.67 to 1.27), and from liver disease of 0.64 (0.12 to 3.59). Compared with participants without steatosis, those with non-alcoholic fatty liver disease and increased liver enzyme levels had adjusted hazard ratios for deaths from all causes of 0.80 (0.52 to 1.22), from cardiovascular disease of 0.59 (0.29 to 1.20), from cancer of 0.53 (0.26 to 1.10), and from liver disease of 1.17 (0.15 to 8.93).

Conclusions: Non-alcoholic fatty liver disease was not associated with an increased risk of death from all causes, cardiovascular disease, cancer, or liver disease.

Citing Articles

Associations of serum folate and vitamin B levels with all-cause mortality among patients with metabolic dysfunction associated steatotic liver disease: a prospective cohort study.

Zhu J, Liao X, Du L, Lv P, Deng J Front Endocrinol (Lausanne). 2024; 15:1426103.

PMID: 39703860 PMC: 11655224. DOI: 10.3389/fendo.2024.1426103.

MAFLD but not MASLD increases risk of all-cause mortality in regional Australia, with components of metabolic syndrome exacerbating factors: 20 year longitudinal, cohort study.

Vaz K, Kemp W, Majeed A, Lubel J, Magliano D, Glenister K Hepatol Int. 2024; .

PMID: 39673677 DOI: 10.1007/s12072-024-10748-5.

Fatty liver index as an independent predictor of all-cause and disease-specific mortality.

Zhang R, Ren S, Mi H, Wang M, He T, Zhang R Eur J Gastroenterol Hepatol. 2024; 36(12):1453-1463.

PMID: 39400538 PMC: 11527378. DOI: 10.1097/MEG.0000000000002865.

Trends of primary liver cancer incidence and mortality in the United States: A population-based study over the last four decades.

Adra S, Alabrach Y, Hashem A, Mahmoud A, Khalouf A, El-Khapery A PLoS One. 2024; 19(9):e0309465.

PMID: 39236039 PMC: 11376511. DOI: 10.1371/journal.pone.0309465.

Association of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) With an Increased Risk of Congestive Heart Failure in Hospitalized Patients With Cirrhosis: A Propensity Score-Matched Analysis.

Ugwendum D, Mohamed M, Al-Ajlouni Y, Nso N, Njei B Cureus. 2024; 16(6):e62441.

PMID: 39011212 PMC: 11249195. DOI: 10.7759/cureus.62441.

References

Sookoian S, Pirola C . Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis: a systematic review. J Hepatol. 2008; 49(4):600-7. DOI: 10.1016/j.jhep.2008.06.012. View

Caldwell S, Oelsner D, Iezzoni J, Hespenheide E, Battle E, Driscoll C . Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology. 1999; 29(3):664-9. DOI: 10.1002/hep.510290347. View

Neuschwander-Tetri B, Clark J, Bass N, Van Natta M, Unalp-Arida A, Tonascia J . Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology. 2010; 52(3):913-24. PMC: 3070295. DOI: 10.1002/hep.23784. View

Teli M, James O, Burt A, Bennett M, Day C . The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology. 1995; 22(6):1714-9. View

Ascha M, Hanouneh I, Lopez R, Tamimi T, Feldstein A, Zein N . The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology. 2010; 51(6):1972-8. DOI: 10.1002/hep.23527. View

Korn E, Graubard B, Midthune D . Time-to-event analysis of longitudinal follow-up of a survey: choice of the time-scale. Am J Epidemiol. 1997; 145(1):72-80. DOI: 10.1093/oxfordjournals.aje.a009034. View

Yamaguchi K, Yang L, McCall S, Huang J, Yu X, Pandey S . Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology. 2007; 45(6):1366-74. DOI: 10.1002/hep.21655. View

Matteoni C, Younossi Z, Gramlich T, Boparai N, Liu Y, McCullough A . Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999; 116(6):1413-9. DOI: 10.1016/s0016-5085(99)70506-8. View

Ong J, Pitts A, Younossi Z . Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. J Hepatol. 2008; 49(4):608-12. DOI: 10.1016/j.jhep.2008.06.018. View

10.

Targher G, Day C, Bonora E . Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med. 2010; 363(14):1341-50. DOI: 10.1056/NEJMra0912063. View

11.

Dunn W, Xu R, Wingard D, Rogers C, Angulo P, Younossi Z . Suspected nonalcoholic fatty liver disease and mortality risk in a population-based cohort study. Am J Gastroenterol. 2008; 103(9):2263-71. PMC: 2574666. DOI: 10.1111/j.1572-0241.2008.02034.x. View

12.

Dam-Larsen S, Becker U, Franzmann M, Larsen K, Christoffersen P, Bendtsen F . Final results of a long-term, clinical follow-up in fatty liver patients. Scand J Gastroenterol. 2009; 44(10):1236-43. DOI: 10.1080/00365520903171284. View

13.

Lazo M, Clark J . The epidemiology of nonalcoholic fatty liver disease: a global perspective. Semin Liver Dis. 2008; 28(4):339-50. DOI: 10.1055/s-0028-1091978. View

14.

Targher G, Bertolini L, Poli F, Rodella S, Scala L, Tessari R . Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. Diabetes. 2005; 54(12):3541-6. DOI: 10.2337/diabetes.54.12.3541. View

15.

Clark J, Diehl A . Nonalcoholic fatty liver disease: an underrecognized cause of cryptogenic cirrhosis. JAMA. 2003; 289(22):3000-4. DOI: 10.1001/jama.289.22.3000. View

16.

Adams L, Sanderson S, Lindor K, Angulo P . The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol. 2005; 42(1):132-8. DOI: 10.1016/j.jhep.2004.09.012. View

17.

Choi S, Diehl A . Hepatic triglyceride synthesis and nonalcoholic fatty liver disease. Curr Opin Lipidol. 2008; 19(3):295-300. DOI: 10.1097/MOL.0b013e3282ff5e55. View

18.

Villanova N, Moscatiello S, Ramilli S, Bugianesi E, Magalotti D, Vanni E . Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease. Hepatology. 2005; 42(2):473-80. DOI: 10.1002/hep.20781. View

19.

Olynyk J, Cullen D, Aquilia S, Rossi E, Summerville L, Powell L . A population-based study of the clinical expression of the hemochromatosis gene. N Engl J Med. 1999; 341(10):718-24. DOI: 10.1056/NEJM199909023411002. View

20.

Ruhl C, Everhart J . Elevated serum alanine aminotransferase and gamma-glutamyltransferase and mortality in the United States population. Gastroenterology. 2008; 136(2):477-85.e11. DOI: 10.1053/j.gastro.2008.10.052. View